applsci-logo

Journal Browser

Journal Browser

Improving Diagnosis and Therapy of Lymphoproliferative Diseases: Latest Advances and Prospects

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 6346

Special Issue Editor


E-Mail Website
Guest Editor
Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy
Interests: chronic lymphocytic leukemia; hairy cell leukemia; Hodgkin lymphoma; targeted drugs; B-cell receptor signaling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic lymphoproliferative diseases are a wide group of rare cancers whose incidence is likely to rise in the next few years. In the last 15 years, our understanding of chronic lymphoproliferative disease in particular of B-cell malignancies has been revolutionized thanks to significant insights into the molecular biology of the disease and the interplay between neoplastic cells and the surrounding microenvironment. The identification of molecules pivotal to the survival of malignant cells has allowed us to develop targeted therapies (monoclonal antibodies, kinase inhibitors, BH3-mimetics, anti-PD-1) that have become the cornerstone of chronic lymphoproliferative diseases. Despite these advances, these diseases remain and hypogammaglobulinemia, infections, and second primary malignancies still impinge upon patients’ quality of life. For this Special Issue, we encourage the submission of original research articles and reviews on any aspect of chronic lymphoproliferative diseases, including diagnostic pitfall, prognostic factor, predictive factors, critical signaling pathways, comorbidities, targeted therapies, the management of kinase inhibitors, monoclonal gammopathies of clinical significance, supporting therapies, and quality of life.

Dr. Andrea Visentin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic lymphocytic leukemia
  • non-Hodgkin lymphoma
  • B-cell malignancies
  • tailored treatment
  • targeted drugs
  • BTK inhibitors
  • BCL2 inhibitors
  • cytogenetic
  • next generation sequencing
  • FISH
  • next generation flow
  • droplet digital PCR
  • Castleman disease
  • antiMAG neuropathy
  • POEMS syndrome
  • prognostic factors
  • predictive factors

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

6 pages, 11710 KiB  
Communication
Necrotizing Follicular Lymphoma of the Inguinal Region with Sternbergoid Cells: Clinical–Pathological Features of a Challenging Entity
by Federico Scarmozzino, Marco Pizzi, Marta Sbaraglia, Luisa Santoro, Luca Frison, Silvia Nalio, Laura Bonaldi, Livio Trentin and Angelo Paolo Dei Tos
Appl. Sci. 2022, 12(3), 1290; https://doi.org/10.3390/app12031290 - 26 Jan 2022
Viewed by 1957
Abstract
Follicular lymphoma (FL) is one of the most common B-cell malignancies worldwide. While the diagnosis of conventional cases is straightforward, rare clinical–pathological variants may be challenging due to their misleading morphology, aberrant phenotype and/or atypical presentation. To add to the spectrum of unusual [...] Read more.
Follicular lymphoma (FL) is one of the most common B-cell malignancies worldwide. While the diagnosis of conventional cases is straightforward, rare clinical–pathological variants may be challenging due to their misleading morphology, aberrant phenotype and/or atypical presentation. To add to the spectrum of unusual FLs, we report on a rare disease pattern characterized by (i) inguinal presentation, (ii) massive necrosis, (iii) Hodgkin/Reed–Sternberg (HRS)-like cells, and (iv) adjacent areas of diffuse large B-cell lymphoma evolution. All cases occurred in elderly patients (median age at diagnosis: 69.5 years), disclosed a low stage at diagnosis (Ann Arbor stage IA-IIA), and had deceiving clinical features. Despite the alarming histology, excellent responses to conventional therapies were reported in all patients. In conclusion, necrotizing FL of the inguinal region is a rare neoplasm characterized by peculiar clinical and histological features. This lymphoma should always be considered in the differential diagnosis of massively necrotic inguinal lesions. Full article
Show Figures

Figure 1

Other

Jump to: Research

5 pages, 213 KiB  
Case Report
Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome
by Francesco Autore, Idanna Innocenti, Federica Sora, Patrizia Chiusolo, Nicola Piccirillo, Andrea Bacigalupo, Simona Sica and Luca Laurenti
Appl. Sci. 2022, 12(5), 2577; https://doi.org/10.3390/app12052577 - 2 Mar 2022
Cited by 2 | Viewed by 1099
Abstract
Autologous stem cell transplantation (ASCT) is a good option in fit young patients affected by POEMS syndrome. Few data are published on how to treat these patients in case of relapse. In this paper we described our two patients who underwent a second [...] Read more.
Autologous stem cell transplantation (ASCT) is a good option in fit young patients affected by POEMS syndrome. Few data are published on how to treat these patients in case of relapse. In this paper we described our two patients who underwent a second ASCT. From our experience, we can confirm that a second transplant is a real treatment option with good results and limited side effects. It provided excellent response and long-term disease-free survival in POEMS patients who relapsed after a first transplant, including late relapses. Full article
5 pages, 615 KiB  
Case Report
A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection
by Alessandro Cellini, Andrea Visentin, Massimiliano Arangio Febbo, Susanna Vedovato, Serena Marinello, Ivo Tiberio, Livio Trentin and Carmela Gurrieri
Appl. Sci. 2022, 12(2), 564; https://doi.org/10.3390/app12020564 - 7 Jan 2022
Viewed by 1154
Abstract
Hemophagocytic Lymphohistiocytosis (HLH) is a rare but life-threatening disease that can occur either as a primary condition or as a consequence of a variety of triggers, including infectious diseases. Here we present a case of secondary HLH triggered by systemic Mycobacterium tuberculosis infection [...] Read more.
Hemophagocytic Lymphohistiocytosis (HLH) is a rare but life-threatening disease that can occur either as a primary condition or as a consequence of a variety of triggers, including infectious diseases. Here we present a case of secondary HLH triggered by systemic Mycobacterium tuberculosis infection in a 59-year-old immunocompromised Hairy Cell Leukemia and previous SARS-CoV2 infected patient. This case report underlines the role of Etoposide-based chemotherapy in treating the severe inflammation that is the defining factor of HLH, suggesting how, even when such therapy is not effective, it may still give the clinicians time to identify the underlying condition and start the appropriate targeted therapy. Moreover, it gives insight on our decision to treat the underlying haematological condition with a BRAF-targeted therapy rather than purine analog-based chemotherapy to reduce the risk of future severe infections. Full article
Show Figures

Figure 1

4 pages, 402 KiB  
Case Report
Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report
by Carmela Gurrieri, Andrea Visentin, Cinzia Bussè, Francesco Piazza, Renzo Manara, Livio Trentin and Chiara Briani
Appl. Sci. 2021, 11(14), 6548; https://doi.org/10.3390/app11146548 - 16 Jul 2021
Cited by 2 | Viewed by 1573
Abstract
Limbic encephalitis is a rare paraneoplastic neurological syndrome usually associated with small cell lung cancers, testicular and breast cancers or B-cell lymphomas. We herein report the first patients with paraneoplastic limbic encephalitis associated with HU antibodies and anaplastic T-cell lymphoma. Full article
Show Figures

Figure 1

Back to TopTop